Rajiv Malik
President at Viatris
Thanks Scott. I appreciate it and look forward to working with you to ensure a smooth transition while continuing to support you as we look out into the future, but in a different capacity. I also want to take the opportunity to thank all of our employees who have helped us build this strong global platform. I'm very pleased with where we are today in Viatris journey. And the strength as well as stability of our core business, which is now nicely set up for the continued growth from here onwards.
Moving to our Commercial segment results. We have delivered a second consecutive quarter of year-over-year operational top line growth as we predicted, which further reaffirms that we are standing strong and set up for the future. This quarter, we recorded 1% year-over-year operational growth and are well positioned to end the full year in line with our expectations. Our well-balanced business of developed markets delivered another strong quarter growing 2% year-over-year operationally. Europe grew 1% versus the prior year on an operational basis, making it the seventh consecutive quarter of year-over-year growth.
France and Italy led the growth in the region. A solid performance of generics in the Europe was another contributing factor. Our North America business was up 4% year-over-year on an operational basis, in line with our expectations. Our generics portfolio performed better than expected, driven by new launches such as Breyna, the generic for Symbicort, [Indecipherable] and the continued contribution of lenalidomide.
Also some other key products, including glatiramer acetate, vancomycin and Xulane performed better than expectations. Our brand business was supported by strong demand in Yupelri, which grew 9% this quarter over the last year and in the epinephrine market. Overall, we remain confident that the developed market segment will meet our full year expectations.
Emerging Markets had another strong quarter and delivered 2% year-over-year operational growth led by strength across our broader generics portfolio and stronger-than-expected performance from brands like Lyrica, Zoloft and Effexor. [Indecipherable] Asia and Turkey were solid performing geographies. This segment is well positioned to deliver mid-single-digit year-over-year growth.
Moving to JANZ, where brands performed in line with our expectations, while generics were slightly below expectations primarily due to customer buying patterns. We continue to be on track to deliver full year expectations. Greater China experienced another solid quarter, primarily driven by strong performance of retail channel in China. Greater China was flat to the prior year, in line with our expectations. We believe that this segment will perform slightly better than our expectations for the full year.
I'm also happy to report steady progress we made on our pipeline in this region. We recently received positive top line results for our Phase III clinical trials of Yupelri in China, which is consistent with our U.S. clinical data, and we look forward to submitting our NDA mid-'24. We currently have 10 other products under health authority review in China.
Moving to the eye care division. As a bridge program sunset, we saw almost 9% non-bridge prescription growth in this quarter. We'll continue to focus on prescription growth in quarter four and into the future. supported by our first direct-to-consumer marketing campaign for Tyrvaya, which we launched in early October. We have recorded $345 million in new product revenue year-to-date and are on track to deliver more than $450 million of revenue from new product launches for the full year.
Let me now discuss some key updates for our R&D pipeline. We are excited by the continued progress of our eye care pipeline, which is aimed at addressing a range of vision-related disorders. All the eye care development programs remain on track, and we are pleased that we received FDA approval for Ryzumvi for the reversal of pharmacologically induced mydriasis and are looking forward to a commercial launch in the U.S. in the first half of '24.
Switching to other pipeline updates, beginning with glatiramer acetate [Indecipherable]. As you recall, the FDA had accepted for review our NDA and it assigned a PDUFA date of March 8, 2024. While we continue to make steady progress regarding the FDA review of our NDA, we are saddened by the tragic situation in Israel. And we are working very closely with our partner, Mapi, who remains fully operational.
We have recently submitted our registration in Europe and are excited about the potential opportunity to bring this product to patients in Europe. Our BOTOX biosimilar program is progressing well from the development, characterization, validation of drug substance and drug product prospective. We recently completed the manufacturing of our IND-enabling drug substance batches and are well on our way to complete the drug product contracting. We remain on track to file our IND by the end of this year. We expect to initiate the pivotal clinical studies for this program in the first half of 2024.
Our Phase III study for our XULANE low-dose program in U.S. remains on track, and we have benefited from an acceleration in the enrollment rate of rate for this study. We now expect to enroll our last patient this December. Also, we are closely interacting with FDA to initiate the Phase III program for our opioid sparing Meloxicam novel product in late December.
Our Phase III study for Effexor, generalized entity disorder in Japan continues to progress according to our schedule. And we remain on target to submit the NDA filing in the first half of 2025.
Finally, all of our complex injectable programs are moving ahead as planned, and we continue to be very excited about the potential of this important potential $1 billion franchise. With that, I will hand the call over to Sanjeev.
